Investigation
BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Menu
Investigation
08/29/2022
Initial Lawsuit
08/30/2022
Lawsuit Progression
10/31/2022
An Azure Power Global Limited (AZRE) investor filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Azure securities between June 15, 2021, and August 26, 2022, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that there were procedural irregularities, including deviations from safety and quality standards, at one of Azure’s plants;
(2) that certain project data was manipulated;
(3) that, as a result of the foregoing, the company’s internal controls and procedures were not effective;
(4) that Azure had received a credible whistleblower report alleging such misconduct; and
(5) that, as a result of the foregoing, the defendants’ positive statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.